Actively Recruiting
Study of OTL78, a PSMA-targeted Fluorescent Agent, for Imaging Prostate Cancer During Surgery to Assess Safety and Effectiveness
Led by Clinton Bahler · Updated on 2026-10-22
45
Participants Needed
2
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the accuracy of a PSMA-targeted fluorescent dye called OTL78 zopocianine combined with Near InfraRed NIR imaging to improve detection of malignant prostate cancer tissue during surgery. This study focuses on adult men with biopsy-confirmed prostate cancer scheduled for prostatectomy and lymph node dissection. The trial aims to confirm previous dose findings and support dose selection for future phase 3 studies. Participants receive a single dose of 0.06 mgkg zopocianine administered 1 to 7 days before their scheduled robotic prostatectomy and lymph node dissection. The dye fluoresces under NIR light to help surgeons identify cancerous tissue during surgery. This open-label trial includes up to 45 men and focuses on determining the optimal dose and timing for the dyes administration. During the study, participants undergo surgery with fluorescent imaging to assess cancer detection and margin status. Researchers monitor for clinically significant events on the day of surgery and follow participants for safety and functional outcomes including urinary continence, sexual function, and PSA levels for up to 12 weeks after surgery. Assessments include adverse event monitoring and evaluation of cancer detection effectiveness, with total participation lasting several weeks post-surgery.
CONDITIONS
Brief Title
Safety and Efficacy of OTL78
Research Team
B
Brandon Garver
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here